Imodium 12 Capsules 2mg

Imodium 12 Capsules 2 mg is an antidiarrheal drug indicated for the treatment of acute and chronic diarrhea. Each capsule contains 2 mg of loperamide hydrochloride, the active ingredient that works by slowing down intestinal movements, thus promoting a greater absorption of liquids and reducing the frequency of discharges. Imodium is indicated for adults and children aged 12 and over, and is effective in rapidly reduce the symptoms of diarrhea, improving stool consistency and reducing fluid loss.

Imodium is indicated for:

• Symptomatic treatment of acute diarrhea in adults and children over 12 years.

• Treatment of chronic diarrhea linked to specific pathological conditions.

• Regulation of stool consistency in patients with ileostomy.

INDICATIONS

Why is Imodium 12 Capsules 2 mg used? What is it for?

Imodium is indicated for the symptomatic treatment of acute diarrhea.

ACTIVE INGREDIENTS AND EXCIPIENTS

What is the composition of Imodium 12 Capsules 2 mg?

One hard capsule contains the active ingredient: loperamide hydrochloride 2 mg. One buccal tablet contains the active ingredient: loperamide hydrochloride 2 mg. One soft capsule contains the active ingredient: loperamide hydrochloride 2 mg. Excipients with known effects. Imodium 2 mg hard capsules: lactose 127 mg. Imodium 2 mg buccal tablets: each tablet contains 750 micrograms of aspartame; the mint flavor contains traces of sulphites. Imodium 2 mg soft capsules: Each soft capsule contains 115.31 mg of propylene glycol. For the full list of excipients, see section 6.1.

Imodium mg hard capsules: lactose, corn starch, talc, magnesium stearate. A green-grey hard capsule consists of: erythrosine (E 127); indigo carmine (E 132); yellow iron oxide (E 172); black iron oxide (E 172); titanium dioxide and gelatin. Imodium 2 mg buccal tablets: gelatin, mannitol, aspartame, mint flavouring, sodium bicarbonate. Imodium 2 mg soft capsules: propylene glycol mono caprylate, propylene glycol, distilled water. One capsule consists of: gelatin, glycerol 99%, propylene glycol, FD&C blue n.1.

DOSAGE

How to take Imodium 12 Capsules 2 mg?

Dosage. Adults: the initial dose is 2 hard capsules or 2 soft capsules or 2 buccal tablets (4 mg). Continue treatment with 1 capsule or 1 tablet (2 mg), after each subsequent evacuation of unformed (soft) stools. The maximum daily dose is 8 capsules or tablets per day (16 mg). Special populations. Children aged between 6 and 17 years (see section 4.3): the initial dose is 1 hard capsule or 1 soft capsule or 1 buccal tablet (2 mg). Continue treatment with 1 capsule or 1 tablet (2 mg), after each subsequent evacuation of unformed (soft) stools. The maximum daily dose in children must be established on the basis of body weight (3 capsules or tablets/20 kg), but must not exceed a maximum of 8 capsules or tablets per day (16 mg). There is limited data available regarding the use of loperamide HCl in children under 12 years of age (see section 4.8 ""Undesirable effects""). Elderly: No dose adjustment is necessary in the elderly. Impaired renal function: No dose adjustment is necessary in patients with impaired renal function. Hepatic impairment: Although no data are available in patients with hepatic impairment, loperamide HCl should be used with caution in these patients due to reduced first pass metabolism (see section 4.4 "Special warnings and precautions for use"). Method of administration. Imodium 2 mg hard capsules/2 mg soft capsules: take by mouth with a little water. Imodium 2 mg buccal tablets: leave the tablet to dissolve on the tongue for a few seconds; the tablet will be dissolved quickly by saliva. It does not require the use of water. Warning: do not use for more than 2 days. In any case, stop treatment when the stool returns to normal, or if you have not had any bowel movements for 12 hours, or if constipation appears. In episodes of acute diarrhea, loperamide HCl is generally able to stop symptoms within 48 hours. After this period without appreciable results, stop treatment and consult your doctor.

CONTRAINDICATIONS AND SIDE EFFECTS

When should Imodium 12 Capsules 2 mg not be used and what side effects can it cause?

Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; children under 6 years old; Pregnancy and breastfeeding (see section 4.6 ""Pregnancy and breastfeeding""). Imodium must not be used as primary therapy: in acute dysentery characterized by the presence of blood in the stool and high fever; in patients with acute ulcerative colitis or pseudomembranous colitis due to the use of broad-spectrum antibiotics; in patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella and Campylobacter. In general, the use of loperamide HCl is contraindicated in all cases where peristalsis inhibition must be initiated due to the possible risk of significant consequences such as ileus, megacolon and toxic megacolon.

Adults and children aged >=12 years Adverse reactions reported in clinical trials with loperamide HCl The safety of Loperamide HCl was evaluated in 3076 adult subjects and children aged >=12 years who took part in 31 controlled and uncontrolled clinical trials with loperamide HCl used for the treatment of diarrhoea. Of these, 26 studies involved acute diarrhea (N=2755) and 5 chronic diarrhea (N=321). The most commonly reported adverse drug reactions (ADRs) (i.e., incidence >=1%) in clinical trials with Loperamide HCl for the treatment of acute diarrhea were as follows: constipation (2.7%), flatulence (1.7%), headache (1.2%), and nausea (1.1%). In clinical trials for the treatment of chronic diarrhea, the most commonly reported ADRs (i.e., >=1% incidence) were as follows: flatulence (2.8%), constipation (2.2%), nausea (1.2%), and dizziness (1.2%). The following list shows ADRs that have been reported with the use of loperamide HCl in clinical trials (in cases of acute or chronic diarrhea) in adults and in children aged >= 12 years. The frequency of adverse reactions presented below is defined using the following convention: very common (>=1/10); common (>=1/100 to <1/10); uncommon (>=1/1,000 to <1/100); rare (>=1/10,000 to <1/1,000); very rare (<1/10,000); not known (frequency cannot be estimated from the available data). Adverse reactions reported with the use of loperamide HCl in clinical trials in adults and children aged >= 12 years. Nervous system disorders. Headache. Acute diarrhea: common; chronic diarrhea: uncommon. Dizziness. Acute diarrhea: uncommon; Chronic diarrhea: common. Gastrointestinal disorders. Constipation, nausea, flatulence. Acute diarrhea: common; Chronic diarrhea: common. Abdominal pain, abdominal discomfort, dry mouth. Acute diarrhea: uncommon; chronic diarrhea: uncommon. Pain in the upper abdomen, vomiting. Acute diarrhea: uncommon. Dyspepsia. Chronic diarrhea: uncommon. Abdominal distension. Acute diarrhea: rare. Pathology of the skin and subcutaneous tissue. Rash. Acute diarrhea: uncommon. Adverse reactions reported in post-marketing experience with loperamide HCl: Determination of adverse reactions through post-marketing experience for loperamide HCl does not distinguish acute and chronic diarrhea indications or adult and pediatric populations; the data collected therefore represents the combination of the indications (acute and chronic diarrhea) and the populations in question (adults and children). Adverse reactions observed during post-marketing experience for loperamide HCl are listed below by System Organ Class, using MedDRA terminology. Adverse reactions reported with the use of loperamide HCl in post-marketing experience in adults and children. Immune system disorders: hypersensitivity reaction, anaphylactic reaction (including anaphylactic shock), anaphylactic reaction. Nervous system disorders: drowsiness, loss of consciousness, stupor, reduced level of consciousness, hypertonia, coordination disorders. Eye pathologies: myosis. Gastrointestinal disorders: ileus (including paralytic ileus), megacolon (including toxic megacolon), glossodynia, acute pancreatitis (frequency not known). Skin and subcutaneous tissue disorders: bullous rash (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme), angioedema, urticaria, pruritus. Renal and urinary disorders: urinary retention. General disorders and conditions relating to the administration site: fatigue. Pediatric population: The safety of loperamide HCl was evaluated in 607 patients aged 10 days to 13 years, who took part in 13 controlled and uncontrolled clinical trials with loperamide HCl used for the treatment of acute diarrhea. Generally speaking, the profile of ADR in this patient population it was similar to that observed in clinical studies with loperamide HCl used in adults and children aged 12 years and older. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system at http://www.agenziafarmaco.gov.it/content/come-segnalare-unasospe tta-reazione-avversa.

INTERACTIONS

Which medicines or foods can change the effect of Imodium 12 Capsules 2 mg?

Non-clinical data have demonstrated that loperamide is a substrate of P-glycoprotein. Concomitant administration of loperamide (in a single dose of 16 mg) with quinidine or ritonavir (both inhibitors of P-glycoprotein) has shown increases in plasma levels of loperamide by 2 to 3 times. The clinical relevance of this pharmacokinetic interaction with P-glycoprotein inhibitors when loperamide is administered at recommended doses (2 to a maximum of 16 mg per day) is unknown. Concomitant administration of loperamide (4 mg single dose) and itraconazole, an inhibitor of CYP3A4 and P-glycoprotein, showed a 34-fold increase in plasma levels of loperamide. In the same study, gemfibrozil, a CYP2C8 inhibitor, showed a 2-fold increase in plasma levels of loperamide. The combination of itraconazole and gemfibrozil showed a 4-fold increase in peak plasma loperamide level and a 13-fold increase in total plasma exposure. These increases were not associated with central nervous system (CNS) effects as detected by psychomotor tests (e.g., subjective dizziness and the Digit Symbol Substitution Test). Concomitant administration of loperamide (single dose of 16 mg) and ketoconazole, an inhibitor of CYP3A4 and P-glycoprotein, showed a 5-fold increase in plasma levels of loperamide. This increase was not associated with an increase in pharmacodynamic effects as detected by pupillometry. Concomitant treatment with oral desmopressin resulted in a 3-fold increase in plasma desmopressin concentrations, presumably due to slowed gastrointestinal motility. Concomitant use of cytochrome CYP450 inhibitors is not recommended. Substances that accelerate gastrointestinal transit may decrease Imodium. Drugs with pharmacological properties similar to those of loperamide or drugs that can slow intestinal peristalsis (e.g. anticholinergics), may increase Imodium.

PREGNANCY AND BREASTFEEDING

Can Imodium 12 Capsules 2 mg be used during pregnancy and breastfeeding?

The administration of Imodium is contraindicated during pregnancy and breastfeeding. Pregnant or breastfeeding women should therefore be advised of the need to consult their doctor for the most appropriate treatment.

WARNINGS

What are the warnings of Imodium 12 Capsules 2 mg?

Treatment of diarrhea with loperamide HCl is symptomatic only. Therefore, where possible, it is also advisable to intervene on the causes of the disorder. In episodes of acute diarrhea, loperamide HCl is generally able to stop the symptoms within 48 hours; after this period without appreciable results, the treatment must be interrupted and the patient must be advised of the need to go to the doctor for a consultation. In patients with diarrhea, especially in children, a significant loss of fluids and electrolytes may occur. In such cases it can be very important to appropriately replenish fluids and electrolytes. Although no pharmacokinetic data are available in patients with hepatic dysfunction, loperamide HCl should be used with caution in these patients due to extensive first-pass metabolism. The drug should be used with caution in patients with hepatic impairment as it can lead to relative overdose with CNS toxicity. AIDS patients treated with loperamide HCl for diarrhea should discontinue therapy at the first signs of abdominal distension. In these patients with infectious colitis of bacterial or viral origin, treated with loperamide HCl, isolated cases of intestinal obstruction with an increased risk of toxic megacolon have been found. If constipation or abdominal or ileal distension occurs, stop treatment immediately. Cases of abuse and misuse of loperamide, used as a substitute for opioids, have been reported in individuals with opioid dependence (see section 4.9). Cardiac events including QT and QRS complex prolongation and torsades de pointes have been reported in association with overdose. Some cases have been fatal (see section 4.9). Overdose can manifest the presence of Brugada syndrome. Patients should not exceed the recommended dose and/or prolong the duration of therapy. Pediatric population: In children between 6 and 12 years of age, Imodium should only be used under medical supervision. There is limited data available regarding the use of loperamide HCl in children under 12 years of age (see section 4.8 ""Undesirable effects""). Important information about some excipients: Imodium 2 mg hard capsules contains lactose. Patients suffering from rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Imodium 2 mg buccal tablets contains: traces of sulphites. Sulfites rarely can cause severe hypersensitivity reactions and bronchospasm; 0.750 mg of aspartame per single dose which is equivalent to 0.011 mg/kg for a 70 kg adult and 0.038 mg/kg for a 20 kg child. Aspartame is hydrolyzed in the gastrointestinal tract when taken orally. One of the major products of its hydrolysis is phenylalanine. No clinical or nonclinical data are available to evaluate the use of aspartame in infants younger than 12 weeks; less than 1 mmol (23 mg) sodium per single dose. It can therefore be considered essentially sodium-free; 0.00066 mg of benzyl alcohol per single tablet. Benzyl alcohol can cause allergic reactions. It is possible that the accumulation of large quantities of benzyl alcohol could cause metabolic acidosis; use with caution and only if necessary, especially in patients with hepatic or renal insufficiency; 0.00003 mg of alcohol (ethanol) in each tablet. The Amount in Ethanol of this medicine is equivalent to less than 0.00000075 ml of beer or 0.0000003 of wine. This medicine contains a quantity of ethanol that does not produce significant effects. Imodium 2 mg soft capsules contains: 115.31 mg of propylene glycol. 115.31 mg of propylene glycol for a single dose, equivalent to 1.65 mg/kg for a 70 kg adult and 5.77 mg/kg for a 20 kg child; less than 1 mmol (23 mg) sodium per single dose. It can therefore be considered essentially sodium-free.

CONSERVATION

How is Imodium 12 Capsules 2 mg stored?

Store the medicine at a temperature not exceeding 25 degrees C.

FORMAT

What is the format of Imodium 12 Capsules 2 mg?

12 Capsules

DRUG LEGAL TEXT

Content responsibility

This sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.

Please note

The product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.

Data source: Farmadati Italia

Website: www.farmadati.it

The Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.

The Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO/IEC 27001:2017 for information security management systems.